Jul 29, 2014 at 17:14 | Source: CNBC-TV18
Consolidated revenue of the company fell 9.6 percent on yearly basis to Rs 2,426.2 crore due to lower exports (declined over 13 percent) while domestic revenue increased by 11.8 percent to Rs 621.6 crore in the quarter gone by.
Jul 28, 2014 at 18:15 | Source: CNBC-TV18
Analysts feel operating profit (EBITDA) may be impacted due to consent decree costs that is expected to be in single digits. They expect mark-to-market gains during the quarter but higher tax rate and weak operational performance may pull down adjusted profit.
Jul 28, 2014 at 11:07 | Source: Moneycontrol.com
According to Ajay Jain, CEO of astromoneyguru.com, pharma, software, media and oil & gas may show positive move in Indian stock market. "Crude oil may show positive movement due to geo-political tension," he adds.
Jul 25, 2014 at 21:22 | Source: CNBC-TV18
The pressure is building up on the Indian drug regulator to clampdown on the fake drugs that are inundating the Indian market. A desperate CDSCO has decided to restart an old scheme -- reward to any whistleblower who is instrumental in the seizure of counterfeit drugs and cosmetics.
Jul 25, 2014 at 16:30 | Source: CNBC-TV18
Mehraboon Irani, Principal and Head- Pvt Client Group Business at Nirmal Bang Securities is of the view that Sun Pharma Advanced Research Company may test Rs 500 in next three years.
Jul 25, 2014 at 11:23 | Source: Moneycontrol.com
According to Ajay Jain, CEO of astromoneyguru.com, one may see profit booking in banking, infrastructure, metal and steel stocks.
Jul 24, 2014 at 11:24 | Source: CNBC-TV18
Independent Market Expert, Ambareesh Baliga feels that Dishman Pharmaceuticals may test Rs 175-180.
Jul 23, 2014 at 11:55 | Source: CNBC-TV18
Here are a few top buzzing stocks picked by CNBC-TV18's analysts in trade today KPIT Technologies, Max India, Ceat, Sun TV, ING Vysya and Strides Arcolab.
Jul 23, 2014 at 10:42 | Source: Moneycontrol.com
With DPCO coverage extending to almost about 40 percent of the industry, the profitability in the domestic business of pharma companies is likely to come under pressure, says an ICRA report.
Jul 21, 2014 at 11:07 | Source: CNBC-TV18
VK Sharma of HDFC Securities recommends a bull spread strategy in Ranbaxy Laboratories wherein on may buy 560 Call and sell 580 Call.